Icyiciro cya 3 Kuvura kanseri y'ibihaha Ntoya: 2026 Iterambere & Igipimo cyo Kurokoka 

Icyiciro cya 3 kitari kanseri yo kuvura kanseri y'ibihaha muri 2026 yahindutse muburyo bukomeye, butandukanye bwo guhuza immunotherapi, kuvura intego, no kubaga neza. Ibimaze kugerwaho byibanda kuri neoadjuvant immun-check point inhibitor kugirango igabanye ibibyimba mbere yo kubagwa hamwe na antibody-ibiyobyabwenge bishya (ADCs) kugirango ihindagurika ryimiterere yihariye. Ibipimo byo kurokoka biratera imbere ku buryo bugaragara, hamwe n’ubushakashatsi buherutse gukorwa bwerekana ko kubaho hagati y’ubuzima butabaho bitarenze amezi 15 ku barwayi bahabwa imiti ikingira indwara nyuma ya chemoradiation.

Gusobanukirwa Icyiciro cya 3 Kanseri y'ibihaha itari mito mito muri 2026

Icyiciro cya 3 kanseri y'ibihaha itari ntoya (NSCLC) yerekana igihe gikomeye muri oncologiya aho iyi ndwara yakwirakwiriye mu mitsi ya lymph hafi ariko ntabwo igera ku ngingo za kure. Iki cyiciro gikunze gusobanurwa nkaho cyateye imbere kandi kikaba gitandukanye cyane, bisaba ingamba zo kuvura kugiti cyawe. Mu 2026, ubusobanuro bwo kuvura bwaragutse, aho abarwayi benshi babonaga ko "badakemurwa" ubu babaye abakandida kubagwa-bagamije kubagwa babikesheje uburyo bwiza bwo kuvura.

Ingorabahizi ya Stage 3 NSCLC iri muburyo butandukanye. Bamwe mu barwayi bagaragaza uruhare ruto rwa nodal bakwiriye kubagwa bidatinze, mu gihe abandi bafite indwara nini zisaba ubuvuzi bwa sisitemu. Uburyo bugezweho bushyira abarwayi mu matsinda adashobora gukemurwa, ashobora gukemurwa, kandi adashobora gukurikiranwa kugira ngo ahuze urukurikirane rwa chimiotherapie, imirasire, immunotherapie, hamwe no kubaga.

• Birashoboka: Ibibyimba bishobora gukurwaho burundu kubagwa mugupima.
• Birashoboka ko byakemurwa: Ibibyimba bishobora gukoreshwa nyuma yo kuvura neoadjuvant (pre-surgery).
• Ntibishoboka: Indwara zateye imbere aho kubaga bidashoboka; bivurwa na chemoradiation isobanutse ikurikirwa no guhuza hamwe.

Gutegura neza ukoresheje amashusho yambere hamwe na molekulari yerekana ni imyitozo isanzwe. Kumenya ihinduka ryimiterere yabashoferi nka EGFR, ALK, cyangwa HER2 ningirakamaro, kuko itegeka niba umurwayi yungukirwa na tirozine kinase inhibitor (TKIs) cyangwa antibody-ibiyobyabwenge aho kuba immunotherapie yonyine.

Iterambere muri Neoadjuvant hamwe nubuvuzi bwigihe

Ihinduka rikomeye muri icyiciro cya 3 kitari gito kuvura kanseri y'ibihaha mu myaka ibiri ishize ni uburyo bwo gukwirakwiza neoadjuvant chemo-immunotherapy. Izi ngamba zirimo gutanga imiti ya chimiotherapie hamwe na inhibitor immunite mbere yo kubagwa. Intego ni ukugera kuri Pathologiya Yuzuye Igisubizo (pCR), aho nta selile zifatika za kanseri ziboneka mubigereranyo byo kubaga, bifitanye isano cyane no kubaho igihe kirekire.

Amakuru y’amavuriro yatanzwe mu nama nkuru ya oncology mu ntangiriro za 2026 yerekana imikorere ya PD-1 inhibitor muri iyi miterere. Ibikoresho nka sintilimab na toripalimab byagaragaje ibisubizo bikomeye mukugabanya ibibyimba no gukuraho lymph node. Ku barwayi bafite kanseri y'udukoko twa kanseri, iyi mikoreshereze yerekanye cyane cyane igipimo cyo gusubiza cyane, bigatuma abantu benshi baterwa na R0 (kuvanaho burundu hamwe n’imipaka mibi).

Uruhare rwo gukurikirana MRD

Iterambere rigezweho muri 2026 ni uguhuza igenzura rito risigaye (MRD). Mu gusesengura ikibyimba kizenguruka ADN (ctDNA) mu maraso nyuma yo kubagwa, abahanga mu bya oncologue barashobora kumenya indwara ya microscopique yerekana amashusho yabuze. Ubushakashatsi buherutse gukorwa burimo aumolertinib ku barwayi ba EGFR-mutant bakoresheje MRD mu kuyobora igihe cyo kuvura. Niba MRD ikomeje kuba mibi, protocole zimwe na zimwe zerekana ko imiti igabanya ubukana kugira ngo igabanye uburozi, mu gihe MRD nziza itera ingamba zikomeye.

Ubu buryo busobanutse neza butuma abarwayi bahabwa imiti bakeneye. Irinda gukabya kurenza abamaze gukira kubagwa kandi itanga ubuvuzi bwa salvage hakiri kare kubafite ibyago byinshi byo kongera kubaho. Ikoreshwa rya MRD riragenda rihinduka biomarker isanzwe mubigeragezo byamavuriro kandi bigira ingaruka kumyifatire ifatika kwisi kubuyobozi bwa Stage 3.

Chemoradiation isobanutse no guhuriza hamwe Immunotherapy

Ku barwayi bafite icyiciro cya 3 NSCLC idashobora gukemurwa, chemoradiation hamwe (cCRT) ikomeza kuba inkingi yubuvuzi. Ariko, imiterere ya nyuma yimirasire yahinduwe no gukingira immunotherapy. Iparadigima yashyizweho namakuru yambere yikigereranyo ya PACIFIC yashimangiwe kandi yagurwa nabakozi bashya hamwe namakuru maremare yo gukurikirana aboneka muri 2026.

Amakuru agezweho ku ngamba zo guhuriza hamwe

Ibyavuye mu bushakashatsi bwakozwe na CONSIST, byatanzwe mu ntangiriro za 2026, bitanga ibimenyetso bifatika byo gukoresha sintilimab nk'ubuvuzi bwo guhuriza hamwe nyuma ya cCRT. Muri ubu bushakashatsi buteganijwe, butandukanye, abarwayi bageze ku kurwanya indwara nyuma ya chemoradiation bahawe sintilimab mu gihe cy’amezi 24. Ibisubizo byerekanaga ubuzima bwo hagati butabaho (PFS) bwamezi 15,6, aho amezi 24 yo kubaho muri rusange agera kuri 80%.

Ibi biremeza ko inhibitori ya PD-1 aribintu bifatika kandi bikomeye muburyo bwa PD-L1 inhibitor mugushira hamwe. Umwirondoro wumutekano washoboraga gucungwa, hamwe nigipimo gito cyibintu bikomeye bikingira indwara. Aya makuru atanga ibyiringiro kubarwayi badashobora kwihanganira ubundi buryo bwo gukingira indwara cyangwa gutura mu turere aho imiti yihariye ishobora kuboneka.

• Ibipimo ngenderwaho: Hamwe na chimiotherapie ishingiye kuri platine.
• Guhuriza hamwe: Gutangiza immunotherapy mugihe cyibyumweru 1-6 nyuma ya cCRT irangiye.
• Igihe rimara: Mubisanzwe byakomeje amezi 12 kugeza 24 niba nta terambere ribaye.

Guhitamo abakozi akenshi biterwa no kwemezwa mukarere nibintu byihariye byabarwayi. Mugihe durvalumab yashyizeho ibipimo byambere, iyinjizwa ryimbere mu gihugu ndetse n’amahanga PD-1 ryashizeho uburyo bwo guhatanira inyungu zifasha abarwayi binyuze mu kongera uburyo ndetse nuburyo butandukanye bwibikorwa.

Ubuvuzi bugenewe kubushoferi-bwahinduwe Icyiciro 3 NSCLC

Igice cyicyiciro cya 3 abarwayi ba NSCLC kibitse abashoferi ba geneti yihariye, cyane cyane ihinduka rya EGFR. Mu mateka, aba barwayi bafashwe kimwe nabadafite ihinduka, ariko 2026 ni umwaka wo gutandukana gutandukanye muburyo bwo kuvura. Imikorere ya EGFR-Tyrosine Kinase Inhibitor (TKIs) mumiterere ya neoadjuvant igenamigambi ubu yanditse neza.

Ubuvuzi bwa EGFR-TKI

Amakuru yashyizwe ahagaragara mu ntangiriro za 2026 yerekeye aumolertinib na osimertinib ashimangira agaciro kabo mukurinda ko abarwayi ba EGFR batongera kubaho. Ubushakashatsi nyabwo bwakorewe mu Bushinwa no mu Burayi bwerekanye ko ubuvuzi bwa TKI bwongerera ubuzima ubuzima butarwaye indwara ugereranije na chimiotherapie yonyine. Ku cyiciro cya IA kugeza ku barwayi ba IIIA bamaze kwangwa burundu, TKI yo mu kanwa iragenda ikundwa cyane kubera imyirondoro yabo myiza n'ingaruka zo kubahiriza.

Byongeye kandi, ubushakashatsi burimo gushakisha uruhare rwa TKIs muburyo bushya bwa neoadjuvant. Ibigeragezo byambere byerekana ko kuvura TKI mugihe gito mbere yo kubagwa bishobora kugabanya neza ibibyimba ku barwayi bafite EGFR, nubwo hakenewe gukurikiranwa neza uburyo bwo guhangana. Urusobe meta-isesengura rwerekanwe mu nama ziheruka zishyigikira ubukuru bwibisekuru bya gatatu TKIs kubisekuruza byabanje murwego rujyanye.

Intego Zivuka: HER2 na KRAS

Kurenga EGFR, izindi ntego zirimo kwiyongera. Guhindura HER2, nubwo bitamenyerewe, ubu birakorwa byemejwe na trastuzumab deruxtecan (T-DXd). Iyi antibody-ibiyobyabwenge conjugate yerekanye imbaraga zidasanzwe mumiterere ya metastatike kandi irimo gukorwaho iperereza ku ndwara zo hambere. Muri ubwo buryo, KRAS G12C inhibitor nka elisrasib irerekana amasezerano mugice cya 1/2 cyibizamini bya NSCLC byavuwe mbere, bikingura amarembo yo kwishyira hamwe muri protocole ya Stage 3.

Amajyambere yo kubaga no Kwishyira hamwe kwa Multimodal

Kubaga bikomeje kuba umuti wonyine ushobora kuvura kanseri y'ibihaha yaho, kandi uruhare rwayo mu cyiciro cya 3 rurasobanurwa hakoreshejwe uburyo bwiza bwo kuvura. Igitekerezo cyo "kubaga guhindura" ni ingenzi kuri 2026 yo kuvura algorithm. Abarwayi babanje kwerekana indwara zidakira kubera uruhare rwa nodal cyangwa ingano y'ibibyimba barashobora kubagwa nyuma yo gukemurwa gukomeye no kuvura neoadjuvant.

Ibipimo byo Kubaga Guhindura

Guhitamo igihe cyo gukora nyuma yubuvuzi bwa neoadjuvant bisaba itsinda ryinshi. Ibintu by'ingenzi birimo urugero rwo kugabanuka kw'ibibyimba, gukuraho lymph node ya mediastinal, hamwe na physiologique yumurwayi. Ubuhanga buhanitse bwo gufata amashusho, harimo PET-CT na MRI, bufasha kubaga gusuzuma neza neza neza kuruta mbere hose.

Tekinike yibasiwe cyane, nka Video-Ifashwa na Thoracoscopic Surgery (VATS) hamwe no kubaga ifashwa na robo, bigenda bikoreshwa cyane no mubice bigoye 3. Ubu buryo bugabanya igihe cyo gukira kandi butuma abarwayi batangira kuvura vuba. Kwishyira hamwe kwa sisitemu yo kugendana hagati yimikorere irusheho kunoza neza gutandukanya lymph node, kwemeza neza no kugenzura neza.

• Isuzuma mbere yo gutangira: Ongera utegure nyuma yubuvuzi bwa neoadjuvant kugirango wemeze hasi.
• Uburyo bwo kubaga: Ibyifuzo byuburyo butagaragara mugihe bishoboka.
• Kwitaho nyuma yubuvuzi: Kwihuta gukira protocole kugirango byorohereze ubuvuzi bwihuse.

Imikoranire hagati yubuvuzi bwa onkologiya no kubaga thoracic ntabwo yigeze ikomera. Ibiganiro bisanzwe byibibyimba byemeza ko buri murwayi wicyiciro cya 3 yakira gahunda ihuriweho cyane itanga amahirwe yo gukira mugihe hagabanijwe uburwayi.

Kugereranya uburyo bwo kuvura icyiciro cya 3 NSCLC

Guhitamo inzira nziza yo kuvura biterwa nibintu byinshi birimo guhinduka, imiterere ya molekile, hamwe nimikorere. Imbonerahamwe ikurikira iragereranya uburyo bwibanze bukoreshwa muri 2026.

Iri gereranya ryerekana ko nta gisubizo-kimwe-gikwiye-igisubizo. Icyerekezo kiragenda kigana mubuvuzi bwihariye aho ibinyabuzima biranga ikibyimba bitera guhitamo imiti. Kurugero, umurwayi ufite ihinduka rya EGFR ashobora kurenga immunotherapie ashyigikira TKI, mugihe umurwayi ufite imvugo ya PD-L1 kandi nta mutation yaba umukandida wambere wa chemo-immunotherapy.

Ibiciro byo kurokoka nibintu biteganijwe muri 2026

Imibare yo kurokoka kuri icyiciro cya 3 kitari gito kuvura kanseri y'ibihaha zirimo gutera imbere, zigaragaza ingaruka ziyi miti mishya. Mugihe amateka yimyaka 5 yo kubaho yabayeho hafi 15-30%, amakuru yiki gihe yerekana ko iyi mibare igenda yiyongera, cyane cyane kubitsinda ryitabira neza ubudahangarwa bw'umubiri.

Ingaruka za Immunotherapie kurokoka igihe kirekire

Gutangiza immunotherapie yibumbiye hamwe byashyizeho "umurizo" kumurongo wo kubaho, bivuze ko igice cyabarwayi bagera kuburwayi bwigihe kirekire byari bisanzwe. Ubushakashatsi bwerekana ko abarwayi barangije amasomo yuzuye yubuvuzi kandi bagakomeza kutagira iterambere mumyaka ibiri bafite amahirwe menshi yo kubaho igihe kirekire.

Mu buryo nk'ubwo, ibyagezweho na pCR nyuma yo kuvura neoadjuvant nubuvuzi bukomeye butanga ibisubizo. Abarwayi bagera kuri pCR bakunze guhura nibyabaye bitabaho kubaho kurenza 80% mumyaka itatu. Ibi byatumye pCR iba iherezo rya surrogate mubigeragezo byinshi byamavuriro, byihutisha iterambere ryimiti mishya.

Ibihinduka

Ibintu byinshi bigira ingaruka kumuntu ku giti cye:

• Imiterere ya Nodal: Umubare hamwe na lymph node zirimo (N1 na N2 na N3) bikomeza kuba ingirakamaro.
• Umwirondoro wa molekulari: Kubaho kwa mutation ikora mubisanzwe bitanga ibisubizo byiza hamwe nubuvuzi bugamije.
• Imikorere: Abarwayi bafite imikorere myiza bihanganira kuvura multimodal ivura neza.
• Igisubizo kuri Induction: Urwego rwo kugabanuka kw'ibibyimba nyuma yubuvuzi bwambere butangaza ko kubaga no kubaho.

Ni ngombwa kumenya ko ibipimo byo kubaho ari impuzandengo. Ibisubizo bya buri muntu biratandukanye cyane bitewe nubuvuzi bwihariye bwakiriwe hamwe n imyitwarire ya kanseri. Intego ya onkologiya igezweho ni uguhindura buri murwayi mubyiciro byiza byateganijwe binyuze mubikorwa byukuri.

Gucunga Ingaruka Zuruhande nubuzima bwiza

Kuvura ubukana kuri Stage 3 NSCLC izana ingaruka zikomeye z'uburozi. Gucunga izo ngaruka ningirakamaro kugirango ugumane urugero rwinshi nubuzima bwiza. Ingaruka zingaruka zinyuranye ziratandukanye cyane hagati ya chimiotherapie, imirasire, immunotherapie, hamwe nibikoresho bigamije.

Immune Bifitanye isano Ibintu bibi (irAEs)

Immunotherapy irashobora gutera uburibwe mu ngingo nzima, izwi nka irAEs. Ibibazo bikunze kugaragara harimo pneumonitis, colitis, dermatitis, n'indwara ya endocrine nka hypotherroidism. Mu bushakashatsi bwa CONSIST, pneumonitis yari impungenge cyane, igaragara ku barwayi bagera kuri 23%, nubwo indwara zikomeye zari gake. Kumenya hakiri kare no gucunga hamwe na corticosteroide ni ngombwa.

Abarwayi bahabwa ubudahangarwa bw'umubiri nyuma yimirasire bafite ibyago byinshi byo kuba uburozi bwibihaha. Gukurikiranira hafi hamwe na CT scan isanzwe hamwe no kugenzura ibimenyetso ni protocole isanzwe. IrAEs nyinshi zirahindurwa iyo zifashwe hakiri kare, zemerera abarwayi gukomeza cyangwa gukomeza kwivuza neza.

Uburozi buva kubuvuzi bugenewe

Ubusanzwe EGFR-TKIs ifite imiterere itandukanye yuburozi, irangwa no kurwara uruhu, impiswi, hamwe nindwara yibihaha rimwe na rimwe. Nubwo akenshi byihanganirwa kuruta chimiotherapie, ubuyobozi budakira busaba kuba maso. Ibisekuru bishya TKI byateje imbere umutekano, ariko gukurikirana umutima hamwe n'ibizamini by'amaso birashobora gusabwa bitewe numukozi wihariye.

• Chimoterapi: Isesemi, umunaniro, neutropenia.
• Imirasire: Esophagitis, reaction y'uruhu, umunaniro.
• Immunotherapy: Autoimmune reaction yibasira ibihaha, amara, uruhu, cyangwa imisemburo.
• Ubuvuzi bugamije: Rash, impiswi, uburozi bwingingo.

Amatsinda yita kubufasha agira uruhare runini mugucunga ibi bimenyetso. Inkunga yimirire, ubuvuzi bwumubiri, hamwe ninama zo mumitekerereze nibice byingenzi byurugendo rwo kuvura, bifasha abarwayi gukomeza imbaraga na morale muburyo bukomeye.

Ahantu heza hazaza: Ibigenda bigaragara hamwe nigeragezwa rya Clinical

Umwanya wa icyiciro cya 3 kitari gito kuvura kanseri y'ibihaha irihuta cyane, hamwe nibigeragezo byinshi byamavuriro byiteguye gusobanura ibipimo mumyaka iri imbere. Icyibandwaho ni uguhindura uburyo bubiri bwo gukingira indwara, ADCs nshya, no guhitamo abarwayi neza ukoresheje biopies.

Ibikurikira-Ibisekuruza Antibody-Ibiyobyabwenge

ADCs iraguka kurenza HER2. Inyubako nshya zigamije TROP2, B7-H3, nizindi antigene ziri mu iterambere. Iyi miti itanga ubushobozi bwo gutanga imiti ikomeye ya chimiotherapie mu ngirabuzimafatizo za kanseri mu gihe irinda ingirangingo zisanzwe. Amakuru yambere muburyo bwa metastatike aratanga ikizere, kandi ibigeragezo birafungura indwara zicyiciro cyambere, harimo nicyiciro cya 3.

Kurugero, abakozi nka YL202 / BNT326 (HER3 ADC) barimo gukorwaho iperereza muburanisha Icyiciro cya 2 kuri NSCLC. Niba bigenze neza, birashobora gutanga amahitamo kubarwayi batitabira ubudahangarwa bw'umubiri cyangwa imiti igamije. Ubwinshi bwa ADCs butuma biba urufatiro rwingamba zizaza.

Inkingo zihariye hamwe nubuvuzi bwa selile

Inkingo za kanseri Intumwa RNA (mRNA) zijyanye na mutation yihariye yumurwayi yinjira mubigeragezo bitinze. Iyo uhujwe na inhibitori ya bariyeri, izi nkingo zigamije gukangura ubudahangarwa bukomeye kandi bwihariye. Byongeye kandi, kuvura ingirabuzimafatizo nka TILs (Tumor-Infiltrating Lymphocytes) zirimo gushakishwa kubyimba bikomeye, bitanga inzira ishobora kuvamo ibibazo.

Kwinjiza ubwenge bwa artile muri gahunda yo kuvura nabyo birihuta. Algorithm ya AI irashobora gusesengura imibare nini yerekana amashusho, genomika, hamwe n’ibisubizo by’amavuriro kugirango hamenyekane uburyo bwiza bwo kuvura abarwayi ku giti cyabo. Uru rwego rwo kwimenyekanisha rusezeranya gukora neza mugihe hagabanijwe uburozi budakenewe.

Ibibazo Bikunze Kubazwa Kubyiciro 3 3 Kuvura NSCLC

Abarwayi nimiryango bakunze kugira ibibazo byinshi mugihe bahuye nicyiciro cya 3. Hano haribisubizo kubibazo bimwe bisanzwe bishingiye kubwumvikane bwubuvuzi 2026.

Icyiciro cya 3 Kanseri y'ibihaha irashobora gukira?

Nibyo, Icyiciro cya 3 NSCLC irashobora gukira, cyane hamwe nubuvuzi bugezweho. Igisobanuro cy "gukiza" akenshi gisobanura kuguma udafite indwara mumyaka itanu cyangwa irenga. Hamwe no gukingira indwara ya neoadjuvant hamwe nubuhanga bunoze bwo kubaga, umubare w’abarwayi bagera ku ndwara ndende uragenda wiyongera.

Umuti umara igihe kingana iki?

Igihe cyo kuvura kiratandukanye. Ubuvuzi bwa Neoadjuvant busanzwe bumara 3-4 (hafi amezi 2-3), hakurikiraho kubagwa no gukira. Ubuvuzi bwa Adjuvant cyangwa guhuriza hamwe burashobora gukomeza kugeza kumyaka 1-2. Ubuvuzi bugamije bushobora gufatwa kumunwa imyaka myinshi bitewe no kwihanganira indwara.

Bigenda bite iyo Kanseri igarutse?

Niba ibisubiramo bibaye, uburyo bwo kuvura buterwa nurubuga nurugero rwo kugaruka. Isubiramo ryaho rishobora kuvurwa kubagwa cyangwa imirasire niba bidakoreshejwe mbere. Metastase ya kure isanzwe ikoreshwa nubuvuzi bwa sisitemu, harimo umurongo wa kabiri wikingira, imiti igamije, cyangwa ibizamini byo kwa muganga. Kuboneka mubyiciro bitandukanye byibiyobyabwenge bivuze ko burigihe hariho imirongo ikurikiraho yo kuvura ubushakashatsi.

• Igenzura: Gusura buri gihe no gusikana ni ngombwa kugirango hamenyekane hakiri kare.
• Amahitamo ya kabiri: Shyiramo ibyiciro bitandukanye byibiyobyabwenge bidakoreshwa mugice cya mbere.
• Ibigeragezo bivura: Akenshi utange uburyo bwo kuvura bugezweho butaraboneka cyane.

Umwanzuro: Igihe gishya cy'amizero no kumenya neza

Imiterere ya icyiciro cya 3 kitari gito kuvura kanseri y'ibihaha muri 2026 bisobanurwa nicyizere nukuri. Inzibacyuho kuva muburyo bumwe-bujyanye nuburyo bwihariye bugira ingamba zihariye cyane byatanze umusaruro ugaragara mubuzima no mubuzima bwiza. Kuva ikoreshwa rya immunoterapi ya neoadjuvant kugeza kunonosora ubuvuzi bwihariye, abarwayi bafite ibikoresho byinshi kuruta ikindi gihe cyose cyo kurwanya iyi ndwara.

Ibyingenzi byingenzi kubarwayi nababitanga harimo akamaro ko gupimwa molekile yuzuye, agaciro kimbaho yibibyimba byinshi, nibikenewe gukurikiza imiti ihuriweho. Mugihe ubushakashatsi bukomeje gufungura intego nshya yibinyabuzima no kunonosora protocole zihari, inzira ya Stage 3 NSCLC amanota ihagaze hejuru. Ubufatanye hagati y’umuryango w’ubushakashatsi ku isi, bugaragazwa no gusangira amakuru mu nama nka ELCC na ASCO, byemeza ko izo ntambwe zigera ku barwayi vuba.

Mugihe ibibazo bikiriho, cyane cyane mugucunga uburozi no kubona ubuvuzi kwisi yose, intambwe imaze guterwa mumyaka mike ishize ntawahakana. Kubantu bose bayobora icyiciro cya 3 muri iki gihe, ubutumwa burasobanutse: hariho inzira nziza, zifashishijwe na siyanse zo kubaho igihe kirekire, kandi ejo hazaza hasezerana byinshi.